Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 95 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 4 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- UK guidelines for the management of soft tissue sarcomas.British journal of cancer · 2025Guideline
- Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence.Archives of gynecology and obstetrics · 2024Pooled it
- Trend of albumin nanoparticles in oncology: a bibliometric analysis of research progress and prospects.Frontiers in pharmacology · 2024Pooled it
- Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis.BMC musculoskeletal disorders · 2023Pooled it
- Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy ofJournal for immunotherapy of cancer · 2025Trial
- Phase II Trial ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Expression of melanocytic markers in uterine smooth muscle tumours.Histopathology · 2026Article
- Statistical optimization of chitosan-based synthesis strategies to generate albumin nanoparticles.Drug delivery and translational research · 2026Article
- Primary Hepatic Perivascular Epithelioid Cell Tumors: From Diagnosis to Treatment.Life (Basel, Switzerland) · 2026Review
- Oral of PtCuS nanoclusters mitigates acute radiation-induced intestinal injury by coordinating glutathione metabolism, macrophage repolarization, and gut microbiota.Materials today. Bio · 2026Article
- TFE3-rearranged PEComa with hepatic and pulmonary involvement: diagnostic challenges and resistance to mTOR-targeted therapy.Journal of cancer research and clinical oncology · 2026Article
- Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling.Cancer research communications · 2026Article
- The many faces of perivascular epithelioid cell tumors: case series illustrating the spectrum of a rare mesenchymal tumor.Journal of surgical case reports · 2026Article
- MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.Nature communications · 2026Article
- Diagnostic utility of novel marker TRIM63 ISH in the workup of uterine perivascular epithelioid cell tumors.Virchows Archiv : an international journal of pathology · 2026Article
- PEComas: current concepts in diagnosis, molecular pathways, and emerging treatments.The oncologist · 2026Review
- How I treat soft tissue sarcomas.Future oncology (London, England) · 2026Review
- Malignant uterine PEComa: a narrative literature review and challenging case report.Journal of cancer research and clinical oncology · 2026Review
- Review
- Malignant hepatic perivascular epithelioid cell tumor: A case report and literature review.Radiology case reports · 2026Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedErratum:2023
Authors and funding
17 authors at 1 institution in 6 countries.
Funding
Abstract
purposeMalignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investigating the safety and efficacy of the mammalian target of rapamycin inhibitor PATIENTS AND
methodsPatients with malignant PEComa were treated with
resultsThirty-four patients were treated (safety evaluable), and 31 were evaluable for efficacy. The overall response rate was 39% (12 of 31; 95% CI, 22 to 58) with one complete and 11 partial responses, 52% (16 of 31) of patients had stable disease, and 10% (3 of 31) had progressive disease. Responses were of rapid onset (67% by week 6) and durable. Median duration of response was not reached after a median follow-up for response of 2.5 years, with 7 of 12 responders with treatment ongoing (range, 5.6-47.2+ months). Twenty-five of 31 patients had tumor mutation profiling: 8 of 9 (89%) patients with a
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.